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Open Forum Infectious Diseases®
Sexually Transmitted Infections Among HIV-Infected 
Individuals in the District of Columbia and Estimated HIV 
Transmission Risk: Data From the DC Cohort
Jose Lucar,1,2,6, Rachel Hart,3 Nabil Rayeed,3 Arpi Terzian,4 Amy Weintrob,1,2 Marc Siegel,1 David M. Parenti,1 Leah E. Squires,2,5 Rush Williams,2,7  
Amanda D. Castel,4 and Debra A. Benator1,2; for the DC Cohort Executive Committee
1Division of Infectious Diseases, The George Washington University Medical Center, Washington, DC; 2Infectious Diseases Section, Veterans Affairs Medical Center, Washington, DC; 3Cerner 
Corporation, Kansas City, Missouri; 4Milken School of Public Health and  5Department of Psychology, The George Washington University, Washington, DC; 6Division of Infectious Diseases, 
University of Mississippi Medical Center, Jackson, Mississippi; 7Columbia Health, Columbia University in the City of New York, New York, New York
Background. Washington, DC, has one of the highest rates of HIV infection in the United States. Sexual intercourse is the lead-
ing mode of HIV transmission, and sexually transmitted infections (STIs) are a risk factor for HIV acquisition and transmission.
Methods. We evaluated the incidence and demographic factors associated with chlamydia, gonorrhea, and syphilis among HIV-
infected persons enrolled at 13 DC Cohort sites from 2011 to 2015. Using Poisson regression, we assessed covariates of risk for inci-
dent STIs. We also examined HIV viral loads (VLs) at the time of STI diagnosis as a proxy for HIV transmission risk.
Results. Six point seven percent (451/6672) developed an incident STI during a median follow-up of 32.5 months (4% chla-
mydia, 3% gonorrhea, 2% syphilis); 30% of participants had 2 or more STI episodes. The incidence rate of any STIs was 3.8 cases 
per 100 person-years (95% confidence interval [CI], 3.5–4.1); age 18–34 years, 10.8 (95% CI, 9.7–12.0); transgender women, 9.9 
(95% CI, 6.9–14.0); Hispanics, 9.2 (95% CI, 7.2–11.8); and men who have sex with men (MSM), 7.7 (95% CI, 7.1–8.4). Multivariate 
Poisson regression showed younger age, Hispanic ethnicity, MSM risk, and higher nadir CD4 counts to be strongly associated with 
STIs. Among those with an STI, 41.8% had a detectable VL within 1 month of STI diagnosis, and 14.6% had a VL ≥1500 copies/mL.
Conclusions. STIs are highly prevalent among HIV-infected persons receiving care in DC. HIV transmission risk is considerable 
at the time of STI diagnosis. Interventions toward risk reduction, antiretroviral therapy adherence, and HIV virologic suppression 
are critical at the time of STI evaluation.
Keywords. District of Columbia; HIV; human immunodeficiency virus; sexually transmitted infections; STI. 
According to data from the Centers for Disease Control and 
Prevention, the District of Columbia had one of the highest incidence 
rates of HIV infection in adults and adolescents living in the United 
States in 2015, at 66.1 cases per 100 000 population [1]. As of 2015, 
the prevalence of HIV infection in DC was 2.0%, which exceeded 
the World Health Organization definition of 1% as a generalized epi-
demic [2]. The leading mode of HIV transmission for new diagnoses 
from 2011 to 2015 was sexual contact (76%). Men who have sex with 
men (MSM) accounted for 58% of those new cases, whereas hetero-
sexually identified men and women accounted for 16%.
Sexually transmitted infections (STIs) are a well known risk 
factor for HIV acquisition and transmission [3–8]. Both ulcer-
ative and nonulcerative STIs provide a portal of entry for HIV 
through mucosal disruption and inflammation, and by increas-
ing HIV RNA in genital secretions. There is a direct correlation 
between plasma and genital HIV RNA concentrations, which 
underscores the importance of antiretroviral therapy (ART) to 
prevent HIV transmission [9]. In the presence of an STI, genital 
HIV shedding can occur despite being on ART with plasma HIV 
RNA suppression [10]. On the other hand, a multicenter rand-
omized controlled trial comparing early vs delayed ART initi-
ation in HIV-serodiscordant heterosexual couples showed that 
early ART was associated with a 93% lower risk of linked-part-
ner infection [11]. Also, a European prospective observational 
study in HIV-serodiscordant heterosexual and MSM couples 
having condomless sex showed no linked HIV transmission 
when the viral load was undetectable on ART [12].
This study aimed to describe the incidence and demographic 
factors associated with the development of chlamydia, gonor-
rhea, and syphilis in people living with HIV in care in DC. We 
also examined plasma HIV viral loads (VLs) at the time of STI 
diagnosis as an approximation of HIV transmission risk.
METHODS
The DC Cohort is a clinic-based, city-wide, longitudinal obser-
vational cohort launched in 2011 to better understand HIV 
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epidemiology in DC, describe clinical outcomes among those in 
care, and improve the quality of care for people living with HIV 
in the DC metropolitan area [13]. At the time of this analysis, 
there were 13 participating outpatient sites: 8 hospital-based clin-
ics and 5 community-based clinics. Following the provision of 
written informed consent, participants’ clinical data was man-
ually entered or electronically exported from patient medical 
records and entered into a web-based data entry system called 
Discovere (Cerner Corporation, Kansas City, MO). Details of the 
DC Cohort study design have been described previously [14, 15].
Study Population and Design
Eligible participants included those enrolled from January 1, 
2011, to March 31, 2015. Participant follow-up time included 
time from enrollment to June 30, 2015, or until the first of these 
occurred: death, withdrawal from the DC Cohort, or loss to 
follow-up. Demographic and clinical characteristics were col-
lected at study enrollment. A descriptive, retrospective cohort 
design was used to examine the incidence of confirmed cases of 
chlamydia, gonorrhea, and syphilis, as well as the VLs in indi-
viduals with any STIs, 1 STI, and 2 or more STIs. As STI screen-
ing may be unevenly applied between study sites, true incidence 
is not known. However, incidence here will refer to those cases 
detected by testing in association with either symptoms or po-
tential exposure, and by clinician- or program-directed screen-
ing in asymptomatic participants.
Participants newly diagnosed with chlamydia, gonorrhea, 
and syphilis more than 30  days after study enrollment were 
defined as incident STI cases. An incident case of chlamydia or 
gonorrhea was defined as a positive nucleic acid amplification 
test (NAAT) or culture on urogenital or extragenital specimens; 
a subsequent new case was accepted as such if there was a pos-
itive test ≥3 weeks after the previous positive test. An incident 
case of syphilis was defined as having (i) positive nontrepone-
mal test (NTr) titer of ≥1:8 with a previous nonreactive NTr, (ii) 
4-fold increase in the NTr titer from the previous test, or (iii) 
positive treponemal test (Tr) if a NTr titer was ≥1:8 and the pre-
vious Tr test was negative. A possible incident syphilis case was 
defined as a single, high-titer NTr test of ≥1:32 that otherwise 
did not fit the criteria for a true incident case. An STI episode 
may include any combination of chlamydia, gonorrhea, and 
syphilis diagnosed at the same date. The occurrence and num-
ber of incident STI episodes among participants was assessed.
To evaluate the HIV transmission potential in individuals 
with incident STIs, we also examined their plasma HIV VLs. We 
determined the VLs at the time of STI diagnosis, defined as the 
VL within ±1 month, 3 months, and 6 months of the STI diag-
nosis date. If a participant had 2 or more STI episodes within 
each ±1-, 3-, or 6-month period, the highest VL was selected. 
Subsequently, we categorized the individuals with STIs as either 
having any number, 1, or 2 or more STIs, as well as their VLs as 
either <1500 or ≥1500 copies/mL. This cutoff was used given 
previous data that HIV-infected persons with VLs higher than 
1500 copies/mL had an increased risk of transmitting HIV to 
others [8, 16]. Because the risk of HIV transmission increases as 
the plasma viral load increases [8, 17], we performed a second 
analysis using the following cutoffs: less than the lower limit 
of quantification (<LLOQ), LLOQ–<1500, 1500–<10 000, and 
≥10 000 copies/mL. Of note, more than 99% of the VLs included 
in this analysis had an LLOQ of either 20 or 40 copies/mL.
Statistical Analysis
Frequencies on demographic and clinical characteristics at 
study enrollment were measured. Differences by factor across a 
specific STI (chlamydia, gonorrhea, syphilis) were determined 
using chi-square test statistics and Fisher exact tests for cat-
egorical variables and Wilcoxon rank-sum tests for continuous 
variables, excluding other and unknown values. Incidence 
rates were calculated per 100 person-years (P-Y) of observa-
tion, using Rothman/Greenland estimation for 95% confidence 
intervals (CIs). Univariate and multivariate Poisson regres-
sion analyses were conducted for factors associated with STIs 
using a Bonferroni correction (to account for multiple testing), 
resulting in a significance level of .05/3 = .0167, and subsequent 
confidence intervals were set at 98.33%. Characteristics with 
unknown values were multiply imputed in the Poisson model. 
All analyses were conducted in SAS 9.4 (Cary, NC).
Ethics
The George Washington University Institutional Review Board 
(IRB), the DC-DOH IRB, and the IRBs of the individual study 
sites approved the study protocol, consent forms, and research 
instruments.
RESULTS
Around the time this data set was closed, the estimated popula-
tion of persons with HIV infection receiving care at the 13 DC 
Cohort sites was 11 235, of which 8732 persons (77.7%) were 
approached for enrollment. Of those persons approached, 7004 
(80.2%) were consented, 948 (10.9%) declined enrollment, 14 
(0.2%) withdrew consent, and 766 (8.8%) remained undecided. 
There were significant differences between those consenting 
and declining, which included female gender (27.8% of those 
consenting vs 36.1% of those declining, P < .0001), white race/
ethnicity (13.1% of those consenting vs 6.6% of those declining, 
P <  .0001), and private insurance status (27.6% of those con-
senting vs 33.2% of those declining, P < .0001).
Among the 6762 participants enrolled in the study between 
January 1, 2011, and March 31, 2015, the median age at con-
sent was 47  years (interquartile range, 36.5–54.5  years); 71% 
were male, 76% were non-Hispanic black, 39% were MSM, 
and 29% were heterosexual participants. There were 113 (2%) 
transgender women and 5 (0.1%) transgender males enrolled in 
the study (Table 1). At the time of consent, 7.8% of participants 
were known to be homeless or have unstable housing, 63.8% 
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Table 1. Baseline Characteristicsa of the DC Cohort Participants by Incident STIs (n = 6762)
Total Chlamydia Gonorrhea Syphilis Any STI
No. Column % No. Row % Column % No. Row % Column % No. Row % Column % No. Row % Column %
6762 250 3.7 212 3.1 123 1.8 451 6.7
Age at enrollment, y
 0–17 149 2.2 10 6.7 4.0 7 4.7 3.3 1 0.7 0.8 11 7.4 2.4
 18–34 1377 20.4 137 9.9 54.8 114 8.3 53.8 45 3.3 36.6 220 16.0 48.8
 35–54 3637 53.8 95 2.6 38.0 80 2.2 37.7 69 1.9 56.1 196 5.4 43.5
 55+ 1599 23.6 8 0.5 3.2 11 0.7 5.2 8 0.5 6.5 24 1.5 5.3
Age at consent, median (IQR) 47.0 (36.5–54.5) 32.8 (25.6–42.3) 32.1 (26.0–42.9) 38.9 (31.6–47.4) 34.8 (26.9–44.3)
Gender at consent
 Male 4823 71.3 210 4.4 84.0 187 3.9 88.2 116 2.4 94.3 392 8.1 86.9
 Female 1821 26.9 29 1.6 11.6 15 0.8 7.1 3 0.2 2.4 39 2.1 8.6
 Transgender female 113 1.7 11 9.7 4.4 10 8.8 4.7 4 3.5 3.3 20 17.7 4.4
 Transgender male 5 0.1 0 0.0 0.0 0 0.0 0.0 0 0.0 0.0 0 0.0 0.0
Race/ethnicityb
 Non-Hispanic black 5161 76.3 169 3.3 67.6 132 2.6 62.3 75 1.5 61.0 290 5.6 64.3
 Non-Hispanic white 940 13.9 54 5.7 21.6 52 5.5 24.5 28 3.0 22.8 101 10.7 22.4
 Hispanic 314 4.6 21 6.7 8.4 23 7.3 10.8 11 3.5 8.9 43 13.7 9.5
 Other 137 2.0 3 2.2 1.2 4 2.9 1.9 1 0.7 0.8 6 4.4 1.3
 Unknown 210 3.1 3 1.4 1.2 1 0.5 0.5 8 3.8 6.5 11 5.2 2.4
HIV risk behaviorc
 MSM 2652 39.2 196 7.4 78.4 181 6.8 85.4 109 4.1 88.6 365 13.8 80.9
 HRH 1989 29.4 23 1.2 9.2 11 0.6 5.2 4 0.2 3.3 35 1.8 7.8
 IDU 452 6.7 1 0.2 0.4 1 0.2 0.5 0 0.0 0.0 2 0.4 0.4
 Other 354 5.2 11 3.1 4.4 8 2.3 3.8 0 0.0 0.0 14 4.0 3.1
 Unknown 1315 19.4 19 1.4 7.6 11 0.8 5.2 10 0.8 8.1 35 2.7 7.8
Nadir CD4 cell count, cells/mm3d
 <50 1056 15.6 17 1.6 6.8 17 1.6 8.0 9 0.9 7.3 37 3.5 8.2
 50–199 1452 21.5 38 2.6 15.2 35 2.4 16.5 30 2.1 24.4 81 5.6 18.0
 200–349 1703 25.2 74 4.3 29.6 72 4.2 34.0 34 2.0 27.6 137 8.0 30.4
 350–499 1265 18.7 63 5.0 25.2 46 3.6 21.7 32 2.5 26.0 107 8.5 23.7
 500+ 1279 18.9 58 4.5 23.2 42 3.3 19.8 17 1.3 13.8 88 6.9 19.5
Housing at index datee
 Permanent/stable 4486 66.3 152 3.4 60.8 124 2.8 58.5 86 1.9 69.9 281 6.3 62.3
 Temporary/unstable/homeless 530 7.8 29 5.5 11.6 31 5.8 14.6 17 3.2 13.8 59 11.1 13.1
 Other 15 0.2 0 0.0 0.0 0 0.0 0.0 0 0.0 0.0 0 0.0 0.0
 Unknown 1731 25.6 69 4.0 27.6 57 3.3 26.9 20 1.2 16.3 111 6.4 24.6
Primary insurance at consentf
 Public 4313 63.8 137 3.2 54.8 119 2.8 56.1 56 1.3 45.5 239 5.5 53.0
 Private 1819 26.9 72 4.0 28.8 60 3.3 28.3 54 3.0 43.9 143 7.9 31.7
 Other 427 6.3 19 4.4 7.6 11 2.6 5.2 9 2.1 7.3 34 8.0 7.5
 Unknown 203 3.0 22 10.8 8.8 22 10.8 10.4 4 2.0 3.3 35 17.2 7.8
Alcohol use at consent
 Yes 906 13.4 49 5.4 19.6 42 4.6 19.8 23 2.5 18.7 89 9.8 19.7
 No 4149 61.4 104 2.5 41.6 83 2.0 39.2 45 1.1 36.6 193 4.7 42.8
 Unknown 1707 25.2 97 5.7 38.8 87 5.1 41.0 55 3.2 44.7 169 9.9 37.5
Substance abuse at consent
 Yes 822 12.2 54 6.6 21.6 49 6.0 23.1 24 2.9 19.5 87 10.6 19.3
 No 3787 56.0 97 2.6 38.8 73 1.9 34.4 52 1.4 42.3 178 4.7 39.5
 Unknown 2153 31.8 99 4.6 39.6 90 4.2 42.5 47 2.2 38.2 186 8.6 41.2
Diagnoses of mental health conditions at consentg 341 5.0 3 0.9 1.2 2 0.6 0.9 0 0.0 0.0 4 1.2 0.9
Ever HBV infection prior to consent 379 5.6 13 3.4 5.2 8 2.1 3.8 10 2.6 8.1 27 7.1 6.0
Ever HCV infection prior to consent 780 11.5 14 1.8 5.6 12 1.5 5.7 7 0.9 5.7 28 3.6 6.2
Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; HRH, heterosexual; IDU, injection drug user; IQR, interquartile range; MSM, men who have sex with men; STI, sexually trans-
mitted infection.
aAll characteristics are at the time of consent into the DC Cohort.
bOther race/ethnicity includes persons of Asian/Pacific Island descent and those with more than 1 reported race.
cHIV risk behaviors: HRH, IDU, MSM. MSM who are also IDUs are grouped with MSM. Other HIV transmission risk behavior includes persons who were perinatally infected or infected 
through blood transfusions, coagulation disorders, or occupational exposures.
dNadir CD4 is the lowest CD4 record available dated prior to enrollment into the DC Cohort. Seven participants had an unknown nadir CD4 cell count.
eTemporary/unstable housing was defined as a housing unit in which persons who are without housing or a fixed address receive temporary housing or shelter.
fPublic insurance includes Medicare, Medicaid, and other public insurance coverage plans; “Other” insurance includes self-pay, recently terminated plans, clinical trial.
gMental health conditions diagnosed previously or at the time of consent include major depressive disorder, anxiety disorder, bipolar disorder, psychoses, other.
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had public insurance and 26.9% had private insurance, 13.4 and 
12.2% had a history of alcohol and substance abuse, respect-
ively, and 11.5% had a hepatitis C diagnosis.
During a median follow-up period of 32.5 months, 6.7% of 
all participants developed an incident STI (n = 451); 3.7% of all 
participants had incident chlamydia infection (n = 250), 3.1% 
gonorrhea (n  =  212), and 1.8% syphilis (n  =  123). There was 
an additional 2.6% with possible incident syphilis that did not 
meet the definition of an incident case. Among participants with 
an incident STI, 30.4% had 2 or more STI episodes (n = 137); 
19.3% had 2 STI episodes (n = 87), 7.3% had 3 (n = 33), 1.8% 
had 4 (n = 8), and 2.0% had 5–8 STI episodes (n = 9). Of all 
the STI episodes, 64.3% were among non-Hispanic blacks and 
22.4% were among non-Hispanic whites. However, 5.6% of all 
enrolled non-Hispanic blacks developed an STI, whereas 10.7% 
of non-Hispanic whites and 13.7% of Hispanics developed an 
STI. Furthermore, 80.9% of individuals who developed an STI 
were MSM (Table 1).
The incidence rate of any STIs in the DC Cohort was 3.8 cases 
per 100 P-Y (95% CI, 3.5–4.1). The highest incidence rates of 
any STIs were noted in the following groups: age 18–34 years 
(10.8 cases per 100 P-Y; 95% CI, 9.7–12.0), transgender females 
(9.9 cases per 100 P-Y; 95% CI, 6.9–14.0), Hispanics (9.2 cases 
per 100 P-Y; 95% CI, 7.2–11.8), and MSM (7.7 cases per 100 
P-Y; 95% CI, 7.1–8.4) (Table 2A). The STI incidence rates were 
stratified for race/ethnicity by age, gender, and risk behavior, as 
well as for age by risk behavior and gender. Taking into account 
the number of participants, the highest incidence rates were 
noted in transgender females age 18–34  years (21.0 cases per 
100 P-Y; 95% CI, 14.0–31.0) and MSM age 18–34 years (15.0 
cases per 100 P-Y; 95% CI, 14.0–17.0). Please refer to Table 2B 
for additional details.
In the univariate Poisson regression model, younger age, male 
gender, transgender women, non-Hispanic white and Hispanic 
race/ethnicity, MSM risk behavior, temporary/unstable hous-
ing, alcohol use, substance abuse, and higher nadir CD4 counts 
were all associated with a higher risk of developing an STI, 
while the presence of a mental health diagnosis and history of 
hepatitis C infection were associated with a lower risk (data not 
shown). In the multivariate Poisson regression model, younger 
age, especially 0–17 and 18–34 years, Hispanic ethnicity, MSM 
risk behavior, and higher nadir CD4 counts remained associ-
ated with a higher risk of developing an STI, while the presence 
of a mental health diagnosis was still associated with a lower 
risk (Table 3).
In the assessment of potential HIV transmission risk at the 
time of STI diagnosis, the VLs were assessed at ±1  month, 
3 months, and 6 months (Table 4). VL measurements were not 
Table 2A. Incidence Rates per 100 Person-Years of Chlamydia, Gonorrhea, and Syphilisa by Baseline Demographic Characteristicsb Among DC Cohort 
Participants (n = 6762)
Chlamydia Gonorrhea Syphilis Any STI
Rate (95% CI) Rate (95% CI) Rate (95% CI) Rate (95% CI)
Overall 1.8 (1.7–2.1) 1.7 (1.5–1.9) 0.8 (0.7–0.9) 3.8 (3.5–4.1)
Age at enrollment, y
 0–17 3.0 (1.7–5.3) 2.3 (1.2–4.4) 0.3 (0–1.8) 5.0 (3.3–7.8)
 18–34 5.7 (5.0–6.6) 5.1 (4.4–5.9) 1.6 (1.2–2.1) 10.8 (9.7–12.0)
 35–54 1.2 (1.0–1.5) 1.1 (0.9–1.3) 0.8 (0.7–1.0) 2.8 (2.5–3.2)
 55+ 0.2 (0.1–0.4) 0.3 (0.2–0.5) 0.2 (0.1–0.4) 0.6 (0.4–0.9)
Gender at consent
 Male 2.1 (1.9–2.4) 2.0 (1.8–2.3) 1.0 (0.9–1.2) 4.6 (4.2–5.0)
 Female 0.7 (0.5–1.0) 0.4 (0.2–0.6) 0.1 (0–0.2) 1.1 (0.9–1.5)
 Transgender female 5.1 (3.1–8.3) 3.8 (2.2–6.7) 1.6 (0.7–3.8) 9.9 (6.9–14.0)
Race/ethnicity
 Non-Hispanic black 1.7 (1.5–1.9) 1.4 (1.2–1.6) 0.6 (0.5–0.8) 3.3 (3.0–3.7)
 Non-Hispanic white 2.5 (2.0–3.2) 2.6 (2.1–3.3) 1.2 (0.8–1.7) 5.3 (4.6–6.3)
 Hispanic 4.2 (2.9–6.0) 4.4 (3.1–6.4) 1.9 (1.1–3.3) 9.2 (7.2–11.8)
 Other 0.9 (0.3–2.8) 1.5 (0.6–3.7) 0.3 (0–2.2) 2.4 (1.2–4.9)
 Unknown 0.5 (0.2–1.5) 0.2 (0–1.1) 1.5 (0.8–2.8) 2.1 (1.2–3.6)
HIV risk behavior
 MSM 3.6 (3.2–4.0) 3.6 (3.2–4.1) 1.7 (1.4–2.1) 7.7 (7.1–8.4)
 HRH 0.5 (0.3–0.7) 0.2 (0.1–0.4) 0.1 (0–0.2) 0.8 (0.6–1.1)
 IDU 0.1 (0–0.5) 0.1 (0–0.5) NA 0.1 (0–0.6)
 Other 1.6 (0.9–2.6) 1.0 (0.5–1.9) NA 2.4 (1.6–3.7)
 Unknown 0.8 (0.6–1.2) 0.4 (0.2–0.7) 0.3 (0.2–0.6) 1.5 (1.1–2.0)
Abbreviations: CI, confidence interval; HRH, heterosexual; IDU, injection drug user; MSM, men who have sex with men; NA, insufficient data for calculation; STI, sexually transmitted 
infection.
aRate per 100 person-years of observation using Rothman/Greenland estimation for 95% confidence intervals.
bAll characteristics are at the time of consent into the DC Cohort.
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Table 2B. Incidence Rates per 100 Person-Years of Chlamydia, Gonorrhea, and Syphilisa by Baseline Demographic Characteristicsb Among DC Cohort 
Participants (n = 6762), Stratified for Race/Ethnicity by Age, Gender, and Risk Behavior
No.
Chlamydia Gonorrhea Syphilis Any STI
Rate (95% CI) Rate (95% CI) Rate (95% CI) Rate (95% CI)
Stratify race/ethnicity by age, y
Non-Hispanic black 0–17 131 3.5 (2.0–6.1) 2.6 (1.3–5.0) 0.3 (0.0–2.0) 5.8 (3.7–8.9)
18–34 1057 5.7 (4.8–6.7) 4.9 (4.1–5.9) 1.5 (1.1–2.1) 10.8 (9.6–12.2)
35–54 2732 0.9 (0.7–1.2) 0.7 (0.5–0.9) 0.6 (0.4–0.8) 2.0 (1.7–2.4)
55+ 1238 0.1 (0.0–0.3) 0.2 (0.1–0.4) 0.1 (0.0–0.2) 0.3 (0.2–0.6)
Non-Hispanic white 0–17 8 NA NA NA NA
18–34 141 7.8 (5.5–11.2) 7.3 (5.1–10.6) 1.6 (0.7–3.5) 13.1 (9.9–17.2)
35–54 537 2.2 (1.6–3.0) 2.4 (1.7–3.3) 1.4 (1.0–2.2) 5.3 (4.3–6.6)
55+ 254 0.6 (0.3–1.5) 0.9 (0.4–1.8) 0.5 (0.2–1.3) 1.9 (1.1–3.1)
Hispanic 0–17 5 NA NA NA NA
18–34 89 6.7 (3.8–11.8) 7.2 (4.2–12.5) 1.1 (0.3–4.5) 13.4 (9.0–20.0)
35–54 170 4.0 (2.5–6.6) 4.3 (2.7–6.9) 2.5 (1.4–4.7) 9.4 (6.8–13.0)
55+ 48 NA NA 1.1 (0.2–8.1) 1.1 (0.2–8.1)
Stratify race/ethnicity by gender
Non-Hispanic black Male 3414 1.9 (1.7–2.2) 1.8 (1.5–2.1) 0.9 (0.7–1.1) 4.1 (3.7–4.5)
Female 1648 0.8 (0.6–1.1) 0.4 (0.2–0.6) 0.1 (0.0–0.2) 1.2 (0.9–1.6)
Transgender Female 96 6.1 (3.7–10.0) 3.4 (1.8–6.6) 1.9 (0.8–4.6) 10.7 (7.4–15.5)
Non-Hispanic white Male 882 2.6 (2.1–3.3) 2.8 (2.2–3.5) 1.2 (0.9–1.8) 5.7 (4.8–6.7)
Female 55 NA NA NA NA
Transgender Female 3 NA NA NA NA
Hispanic Male 270 4.7 (3.2–6.8) 4.7 (3.2–6.8) 2.2 (1.3–3.8) 10.1 (7.8–13.0)
Female 31 NA NA NA 0.0 (0.0–)
Transgender Female 11 NA 6.6 (1.6–26.2) NA 6.6 (1.6–26.2)
Stratify race/ethnicity by risk behavior
Non-Hispanic black MSM 1620 3.8 (3.3–4.5) 3.6 (3.1–4.2) 1.7 (1.3–2.1) 8.1 (7.3–8.9)
HRH 1792 0.5 (0.3–0.8) 0.2 (0.1–0.4) 0.1 (0.0–0.2) 0.8 (0.6–1.1)
IDU 425 0.1 (0.0–0.6) NA NA 0.1 (0.0–0.6)
Other 292 1.9 (1.1–3.3) 1.2 (0.6–2.4) NA 3.0 (2.0–4.6)
Unknown 1029 0.7 (0.4–1.1) 0.4 (0.2–0.8) 0.4 (0.2–0.7) 1.4 (1.0–2.0)
Non-Hispanic white MSM 667 3.3 (2.6–4.2) 3.6 (2.9–4.6) 1.6 (1.1–2.3) 7.3 (6.2–8.6)
HRH 58 NA NA NA NA
IDU 19 NA NA NA NA
Other 37 NA NA NA NA
Unknown 159 0.9 (0.3–2.3) 0.2 (0.0–1.5) 0.2 (0.0–1.5) 1.3 (0.6–2.9)
Hispanic MSM 194 4.7 (3.1–7.2) 6.0 (4.2–8.7) 2.4 (1.3–4.3) 11.2 (8.5–14.7)
HRH 57 1.0 (0.1–6.8) NA 1.0 (0.1–6.8) 1.9 (0.5–7.7)
IDU 4 NA 18.8 (2.7–133.6) NA 18.8 (2.7–133.6)
Other 9 NA NA NA NA
Unknown 48 6.7 (2.8–16.0) 1.3 (0.2–9.5) 1.3 (0.2–9.5) 9.3 (4.4–19–5)
Stratify age by risk behavior
MSM 5 24.0 (6.0–95.0) 24.0 (6.0–95.0) 12.0 (1.7–85.0) 48.0 (18 127.0)
HRH 8 16.0 (5.1–49.0) 5.2 (0.7–37.0) NA 21.0 (7.9–56.0)
IDU 0 NA NA NA NA
Other 132 1.9 (0.9–4.1) 1.7 (0.7–3.7) NA 3.3 (1.9–5.9)
 0–17 y Unknown 4 NA NA NA NA
MSM 796 7.7 (6.5–9.0) 7.8 (6.7–9.2) 2.4 (1.8–3.1) 15.0 (14.0–17.0)
HRH 300 2.1 (1.3–3.4) 1.0 (0.5–2.0) 0.3 (0.1–1.1) 3.0 (2.0–4.6)
IDU 5 NA 9.5 (1.3–67.0) NA 9.5 (1.3–67.0)
Other 120 2.2 (1.0–4.8) 1.1 (0.3–3.3) NA 3.2 (1.7–6.2)
 18–34 y Unknown 155 5.5 (3.5–8.8) 1.5 (0.6–3.7) 1.2 (0.5–3.3) 8.0 (5.4–12.0)
MSM 1433 2.5 (2.1–3.0) 2.4 (1.9–2.9) 1.8 (1.4–2.2) 5.9 (5.2–6.7)
HRH 1200 0.3 (0.1–0.5) 0.1 (0.0–0.3) 0.1 (0.0–0.3) 0.5 (0.3–0.8)
IDU 156 NA NA NA NA
Other 72 0.5 (0.1–3.8) NA NA 0.5 (0.1–3.8)
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available for 116 (25.7%) participants at ±1 month, 44 (9.8%) 
at ±3 months, and 29 (6.4%) at ±6 months after STI diagnosis. 
Although VL measurements were missing for 25.7% of partic-
ipants at the assessment closest to the STI episode, VL results 
were similar to those at 3 and 6 months and therefore assumed 
to be representative. Among individuals with any number 
of STI episodes, 41.8% had a detectable viral load (above the 
LLOQ) within 1 month of the STI diagnosis; 14.6% had a VL 
≥1500 copies/mL. For those with 1 STI episode, 13.5% had a VL 
≥1500 copies/mL and 7.4% had a VL ≥10 000 copies/mL. These 
percentages were higher in participants with 2 or more STI epi-
sodes; 17.1% had a VL ≥1500 copies/mL, and 13.3% had a VL 
≥10 000 copies/mL. However, these differences did not achieve 
statistical significance.
DISCUSSION
In this large-scale, single city–focused analysis, we reported the 
incidence and factors associated with the development of chla-
mydia, gonorrhea, and syphilis in a cohort of people living with 
HIV (PLWH) in care in DC. Consistent with incidence rates 
among the DC general population [2], chlamydia had the high-
est incidence, followed by gonorrhea and then syphilis, each 
with particularly high rates among 18–34-year-olds, MSM, 
transgender women, and Hispanic participants.
Among age, gender, race/ethnicity, and risk categories, 
18–34-year-olds, transgender women, Hispanics, and MSM 
had the highest STI incidence rates. In our stratified analysis, 
the populations at particularly high risk included 18–34-year-
olds of all races/ethnicities, MSM of all races/ethnicities, 
Hispanic men, and non-Hispanic black transgender women. 
All groups were at substantial risk of STIs, with incidence 
rates ranging from 7.3 to 13.4 cases per 100 P-Y. Although 
the overall number of transgender women enrolled in the DC 
Cohort was relatively low, at 113, this sample size afforded 
an opportunity for comparison of risk across the larger HIV-
infected population overall and other high-risk populations. 
The very high risk of STIs identified among transgender 
women highlights the importance of strategies to reduce STI 
and HIV transmission that are culturally and gender sensitive 
across all at-risk groups.
In the multivariate analysis of factors associated with STI 
risk, younger age (especially <18 and 18–34  years), Hispanic 
ethnicity, MSM risk behavior, and higher nadir CD4 counts 
were strongly associated with a higher risk of developing an 
STI. It has been hypothesized that with higher CD4 counts (as 
a consequence of virologic suppression on ART), patients may 
perceive a lower “threat” of HIV transmission and therefore 
have higher-risk sexual behaviors [18–20]. To date, this associ-
ation has not been proven [21–23], but our data on CD4 counts 
may suggest a potential association between improved general 
well-being and high-risk sexual behaviors. Certainly, it has been 
proposed that the greatest prevalence of STIs in PLWH is at the 
time of HIV diagnosis [24]. However, it is also widely recognized 
that high-risk sexual behaviors can continue at any point after 
No.
Chlamydia Gonorrhea Syphilis Any STI
Rate (95% CI) Rate (95% CI) Rate (95% CI) Rate (95% CI)
 35–54 y Unknown 772 0.3 (0.1–0.7) 0.3 (0.1–0.7) 0.3 (0.1–0.7) 0.8 (0.5–1.4)
MSM 417 0.5 (0.2–1.1) 0.9 (0.5–1.7) 0.5 (0.2–1.1) 1.8 (1.1–2.7)
HRH 481 NA NA 0.1 (0.0–0.6) 0.1 (0.0–0.6)
IDU 291 0.1 (0.0–0.8) NA NA 0.1 (0.0–0.8)
Other 29 NA NA NA NA
 55+ y Unknown 381 0.2 (0.1–0.9) 0.1 (0.0–0.8) 0.1 (0.0–0.8) 0.5 (0.2–1.2)
Stratify age by gender
Male 61 3.1 (1.3–7.5) 1.9 (0.6–5.8) 0.6 (0.1–4.4) 5.0 (2.5–10)
Female 88 3.0 (1.4–6.2) 2.5 (1.1–5.6) NA 5.1 (2.9–8.9)
 0–17 y Transgender female 0 NA NA NA NA
Male 993 6.6 (5.6–7.7) 6.2 (5.3–7.3) 2.0 (1.5–2.6) 13.0 (11–14)
Female 338 2.3 (1.5–3.7) 1.2 (0.6–2.2) NA 3.3 (2.2–4.8)
 18–34 y Transgender female 45 10 (5.7–18.0) 9.1 (5.1–16.0) 3.3 (1.2–8.8) 21.0 (14.0–31.0)
Male 2552 1.5 (1.3–1.9) 1.5 (1.2–1.8) 1.1 (0.9–1.4) 3.7 (3.3–4.2)
Female 1024 0.3 (0.1–0.6) 0.1 (0.0–0.3) 0.1 (0.0–0.3) 0.4 (0.2–0.8)
 35–54 y Transgender female 57 1.8 (0.6–5.6) 0.6 (0.1–4.3) 0.6 (0.1–4.3) 3.0 (1.2–7.2)
Male 1217 0.2 (0.1–0.5) 0.4 (0.2–0.6) 0.2 (0.1–0.4) 0.7 (0.5–1.1)
Female 371 NA NA 0.1 (0.0–0.8) 0.1 (0.0–0.8)
 55+ y Transgender female 11 3.8 (0.5–27.0) 0.0 (0.0–0.0) NA 3.8 (0.5–27)
Abbreviations: CI, confidence interval; HRH, heterosexual; IDU, injection drug user; MSM, men who have sex with men; NA, insufficient data for calculation; STI, sexually transmitted 
infection.
aRate per 100 person-years of observation using Rothman/Greenland estimation for 95% confidence intervals.
bAll characteristics are at the time of consent into the DC Cohort.
Table 2B. Continued
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HIV diagnosis [25, 26]. Thus, though risk may be reduced com-
pared with before HIV diagnosis, this study demonstrates that 
ongoing STI and HIV transmission risk remains considerable.
There is significant heterogeneity between previous studies 
of STIs among PLWH in other large metropolitan areas of the 
United States [24]. Hence, the comparison between our STI 
prevalence (6.7% over a median follow-up of 32.5 months) and 
incidence (3.8 cases per 100 P-Y) with other cohorts should be 
interpreted with caution. There are several studies that examine 
the incidence of bacterial STIs, but many of them focus on spe-
cific groups (eg, men, MSM, women) or settings (eg, STI clin-
ics, military personnel). For example, a study on self-reported 
STIs via structured computer interviews in PLWH in Atlanta, 
Georgia, showed that 14% of respondents had an STI diagnosed 
Table 3. Multivariate Poisson Regression Analysis for Factors Associated With the Development of STIs Among Participants in the DC Cohort
Participant Characteristic
Chlamydia Gonorrhea Syphilis Any STI
RR (95% CI) Pg RR (95% CI) P RR (95% CI) P RR (95% CI) P
Age at consent, y
0–17 24.2 (7.3–80.4) <.0001 23.5 (7.2–76.6) <.0001 2.5 (0.3–20.1) .40 17.6 (7.2–42.9) <.0001
18–34 15.7 (7.9–31.4) <.0001 9.9 (5.4–18.2) <.0001 6.1 (2.8–13.2) <.0001 9.4 (6.2–14.1) <.0001
35–54 4.4 (2.2–8.8) <.0001 2.9 (1.6–5.2) .001 3.9 (1.8–8.1) .000 3.3 (2.2–4.9) <.0001
55+ Ref Ref Ref Ref
Gender at consenta
Male Ref Ref Ref Ref
Female 0.8 (0.5–1.3) .385 0.6 (0.4–1.2) .143 0.1 (0–0.3) <.0001 0.7 (0.5–1) .0316
Transgender female 1.3 (0.8–2.2) .335 1 (0.5–1.8) .945 1.3 (0.5–3.3) .53 1.2 (0.8–1.8) .3053
Race/ethnicity
Non-Hispanic black Ref Ref Ref Ref
Non-Hispanic white 1.3 (0.9–1.7) .12 1.5 (1.1–2) .009 1.3 (0.8–2) .23 1.2 (1–1.5) .05
Hispanic 1.4 (0.9–2.1) .130 1.7 (1.1–2.5) .009 1.7 (0.9–3) .095 1.5 (1.1–1.9) .008
Other 0.5 (0.2–1.5) .21 1 (0.4–2.4) .95 0.4 (0.1–2.7) .33 0.6 (0.3–1.2) .18
HIV risk behaviorb
MSM Ref Ref Ref Ref
HRH 0.3 (0.2–0.4) <.0001 0.1 (0.1–0.3) <.0001 1.3 (0.7–2.4) .325 0.2 (0.1–0.3) <.0001
IDU 0.1 (0–1.4) .088 0.1 (0–1) .045 0.2 (0–0.8) .022 0.1 (0–0.7) .03
Other 0.3 (0.1–0.8) .02 0.2 (0–0.5) .001 0.6 (0.4–0.9) .01 0.2 (0.1–0.5) <.001
Housing at consentc
Permanent/stable Ref Ref Ref Ref
Temporary/unstable 1 (0.7–1.5) .84 1.2 (0.8–1.9) .29 1.8 (0.9–3.5) .12 1.2 (1–1.6) .089
Homeless 0.9 (0.4–2.3) .88 1.5 (0.4–6.3) .54 1.6 (0.9–2.6) .08 0.8 (0.4–1.6) .52
Primary insuranced
Public 1.3 (1–1.8) .039 1.5 (1.1–2) .020 1.3 (0.7–2.3) .444 1.2 (1–1.5) .062
Private Ref Ref Ref Ref
Other 1.2 (0.6–2.4) .576 0.7 (0.2–2) .480 1.3 (0.7–2.5) .374 1.2 (0.8–2) .3727
Alcohol use 1.2 (0.8–1.9) .320 1.2 (0.8–1.7) .442 0.7 (0.4–1.4) .355 1.2 (0.9–1.6) .1598
Substance abuse 1.3 (0.8–2.1) .194 1.4 (1–2) .056 2.2 (1.1–4.4) .034 1.3 (1–1.7) .0345
Mental health diagnosis at consente 0.3 (0.1–1) .044 0.4 (0.1–1.1) .072 2 (1–4) .063 0.3 (0.1–0.6) .0028
Ever HBV infection prior to consent 0.9 (0.5–1.5) .631 0.7 (0.4–1.3) .316 2.6 (1.3–5.2) .009 0.9 (0.7–1.3) .7119
Ever HCV infection prior to consent 1 (0.6–1.5) .880 0.7 (0.4–1.2) .215 1.8 (0.9–3.8) .124 0.9 (0.7–1.3) .5952
Nadir CD4 cell countf
<50 Ref Ref Ref Ref
50–199 1.5 (0.9–2.6) .108 1.3 (0.8–2.2) .29 1.3 (0.8–2.2) .290 1.5 (1.1–2.1) .017
200–349 2.6 (1.6–4.2) <.0001 2.2 (1.4–3.5) .001 2.2 (1.4–3.5) .001 2.2 (1.6–3) <.0001
350–499 2.2 (1.4–3.6) .0015 1.8 (1.1–3) .014 1.8 (1.1–3) .014 1.9 (1.4–2.7) <.0001
500+ 2.4 (1.4–3.9) .0007 1.7 (1.1–2.9) .028 1.7 (1.1–2.9) .03 1.9 (1.4–2.7) .00
Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; HRH, heterosexual; IDU, injection drug user; MSM, men who have sex with men; Ref, reference group; RR, relative risk; STI, 
sexually transmitted infection.
aTransgender men were not included in this analysis due to the small number (n = 5).
bOther HIV transmission risk behavior includes persons who were perinatally infected or infected through blood transfusions, coagulation disorders, or occupational exposures.
cTemporary/unstable housing was defined as a housing unit in which persons who are without housing or a fixed address receive temporary housing or shelter.
dPublic insurance includes Medicare, Medicaid, and other public insurance coverage plans; “Other” insurance includes self-pay, recently terminated plans, clinical trial.
eMental health conditions diagnosed previously or at the time of consent include major depressive disorder, anxiety disorder, bipolar disorder, psychoses, other.
fNadir CD4 is the lowest CD4 record available dated prior to enrollment into the DC Cohort. Seven participants had an unknown nadir CD4 cell count.
gA Bonferroni correction was applied to account for multiple testing, resulting in a significance level of .05/3 = .0167, and subsequent confidence intervals set at 98.33%.
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in the previous 6 months, with a high frequency of STIs ever 
since HIV diagnosis (20% had chlamydia, 13% had gonorrhea, 
and 36% had syphilis) [25]. In contrast, in a cohort of HIV-
infected Department of Defense beneficiaries, the prevalence of 
syphilis at the time of HIV diagnosis was 6%; the incidence rate 
was 1.3 cases per 100 P-Y [21]. As expected, published studies 
in which HIV-infected individuals were tested following STI 
screening protocols reported higher STI rates [27, 28] and are 
more likely to approach a true STI incidence.
Virologic suppression with antiretroviral therapy has been 
widely recognized as the key intervention to prevent HIV 
transmission, as recently confirmed in 2 large studies [11, 12]. 
There have been multiple attempts in the past to determine the 
extent to which STI control could impact HIV transmission, 
with mixed results [29–31]. Nevertheless, even when we fail 
to impact high-risk sexual behaviors, it is possible to interrupt 
HIV transmission if the VL is suppressed. Arguably the most 
important (and disappointing) finding of our analysis was the 
fact that 41.8% of participants with at least 1 STI episode had a 
detectable VL within 1 month of STI diagnosis. Furthermore, 
when using ≥1500 copies/mL as a proxy for transmission risk 
(albeit based on data in heterosexual transmission), 14.5% had 
≥1500 copies/mL. Sustained virologic suppression among indi-
viduals with ongoing risk behaviors, signaled by the occurrence 
of an STI, may prevent HIV transmission from an infected 
sexual partner, and thus new HIV cases. Additionally, a nota-
ble finding from our data is the absence of VL measurement 
on 25.7% of those with STIs within ±1 month of STI diagnosis, 
9.8% within ±3 months, and 6.4% at ±6 months. Yet our finding 
that 41.8% of participants within 1 month of STI diagnosis had 
a detectable VL should be an important reminder that presenta-
tion for STI evaluation is also a critical opportunity to address 
ART adherence and virologic suppression.
The DC Cohort database is linked semi-annually with the DC 
Department of Health (DC-DOH) HIV/AIDS surveillance data-
base to enhance data accuracy, as individuals may receive care at 
multiple clinical sites. After completing our planned STI analyses, 
we examined linked data and found a 9.2% increase in the number 
of chlamydia cases (from 250 to 273 cases) and a 20.8% increase in 
the number of cases of gonorrhea (from 212 to 256 cases) during the 
period of study (unpublished data). These findings highlight that 
linkage to care and virologic suppression opportunities may also 
require cross-site communication. We propose specifically that at 
each encounter for STI evaluation and/or treatment, even outside of 
the usual site of HIV care, a focused discussion and intensive efforts 
toward engagement in care and virologic suppression should be 
provided. This high-impact intervention among those potentially 
transmitting HIV not only provides profound individual benefit, 
but may also prevent new HIV cases in the community.
This study has several limitations. First, the observational 
nature of the DC Cohort precluded standardized STI screening 
for all participants. STIs are frequently asymptomatic, and dif-
ferences in screening practices can impact the observed STI fre-
quency [32, 33]. Subsequently, our reported STI incidence rates 
are likely underestimating the true STI incidence in PLWH in 
care in DC. Furthermore, STI screening may provide diagnosis 
dates distant from the actual time of STI acquisition with impli-
cations in our estimation of HIV transmission risk. Similarly, 
the study design also limited the availability of HIV VLs during 
the same encounter of STI diagnosis. Second, we were unable to 
distinguish genital or extragenital sites of chlamydia and gonor-
rhea infection. Third, the population enrolled in the DC Cohort 
may not be fully representative of the larger HIV-infected pop-
ulation in DC, as enrollment requires some degree of engage-
ment in care, and the demographics of those declining consent 
differed slightly from those who provided consent.
Nonetheless, the strengths of this study include its city-wide, 
prospective enrollment of participants, its longitudinal study 
design, and the large sample size that is inclusive of male, female, 
and transgender participants. Also, our study is unique in link-
ing data from multiple clinical sites with data reported to the 
local health department. Merging of the DC Cohort and the 
DC-DOH databases improved the accuracy of STI diagnosis fre-
quency and provided insight into care received for STIs outside 
of the primary HIV care site. Finally, to our knowledge, this is the 
largest cohort to examine the occurrence of STIs and estimated 
HIV transmission risk in the DC metropolitan area, which has 
one of the highest incidence rates of HIV in the United States.
In conclusion, STIs are frequent among HIV-positive indi-
viduals receiving care in DC; thus risk reduction interventions 
are needed for people living with HIV to help control the spread 
of STIs, achieve durable HIV virologic suppression, and reduce 
Table 4. HIV Viral Load in Participants With at Least 1 STI Episode (<LLOQ, LLOQ–<1500, 1500–<10 000, and ≥10 000 copies/mL) Within ±1 Month, ±3 Months, 
and ±6 Months of STI Diagnosis (n = 451)
Participants 
with at least 1 
STI episode
Within 1 mo Within 3 mo Within 6 mo
<LLOQ
LLOQ– 
<1500 1500–9999 ≥10 000 <LLOQ
LLOQ– 
<1500 1500–9999 ≥10 000 <LLOQ
LLOQ– 
<1500 1500–9999 ≥10 000
451 195 (58.2%) 91 (27.2%) 18 (5.4%) 31 (9.3%) 241 (59.4%) 108 (26.6%) 19 (4.7%) 38 (9.4%) 253 (60.0%) 112 (26.5%) 19 (4.5%) 38 (9.0%)
One hundred sixteen participants (25.7%) did not have a VL recorded within ±1 month, 44 participants (9.8%) did not have a VL recorded within ±3 months, and 29 (4.4%) participants did 
not have a VL recorded within ±6 months of STI diagnosis. 
Abbreviations: LLOQ, lower limit of quantification; STI, sexually transmitted infection; VL, viral load.
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HIV transmission. These findings will help health care pro-
viders and policy makers provide high-impact interventions 
toward STI control and achievement of virologic suppression 
among PLWH with the goal of improving the health of the indi-
vidual and reducing the incidence of HIV in the community.
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